MX420412B - Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr. - Google Patents
Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr.Info
- Publication number
- MX420412B MX420412B MX2020012799A MX2020012799A MX420412B MX 420412 B MX420412 B MX 420412B MX 2020012799 A MX2020012799 A MX 2020012799A MX 2020012799 A MX2020012799 A MX 2020012799A MX 420412 B MX420412 B MX 420412B
- Authority
- MX
- Mexico
- Prior art keywords
- plinabulin
- compositions
- treatment
- cancer associated
- egfr mutation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679619P | 2018-06-01 | 2018-06-01 | |
| PCT/US2019/034726 WO2019232257A1 (en) | 2018-06-01 | 2019-05-30 | Composition and method of treating cancer associated with egfr mutation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020012799A MX2020012799A (es) | 2021-03-25 |
| MX420412B true MX420412B (es) | 2025-02-10 |
Family
ID=68696755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012799A MX420412B (es) | 2018-06-01 | 2019-05-30 | Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210161888A1 (enExample) |
| EP (1) | EP3801524B1 (enExample) |
| JP (1) | JP7500438B2 (enExample) |
| KR (1) | KR102790127B1 (enExample) |
| CN (1) | CN112543636B (enExample) |
| AU (1) | AU2019278886B2 (enExample) |
| CA (1) | CA3101612A1 (enExample) |
| DK (1) | DK3801524T3 (enExample) |
| ES (1) | ES3060133T3 (enExample) |
| MX (1) | MX420412B (enExample) |
| WO (1) | WO2019232257A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202008673WA (en) | 2015-03-06 | 2020-10-29 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| JP2019511565A (ja) | 2016-02-08 | 2019-04-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | ツカレゾールまたはそのアナログを含む組成物 |
| AU2017278245B2 (en) | 2016-06-06 | 2022-09-15 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20240110997A (ko) | 2017-02-01 | 2024-07-16 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| EP3743074A4 (en) | 2018-01-24 | 2021-12-15 | Beyondspring Pharmaceuticals Inc. | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE |
| WO2022216908A1 (en) | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| KR20240082379A (ko) * | 2021-10-03 | 2024-06-10 | 시스트이뮨, 인코포레이티드 | 암 치료 방법 및 이의 약제학적 조성물 |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| KR20260019493A (ko) * | 2023-06-02 | 2026-02-10 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 종양 병용 요법 및 사용 방법 |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60316688T2 (de) * | 2002-08-02 | 2008-07-17 | Nereus Pharmaceuticals, Inc., San Diego | Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| CA2939165A1 (en) * | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | A cdp-camptothecin conjugate, particle or composition and uses thereof |
| LT2958943T (lt) * | 2013-02-20 | 2020-01-27 | The Trustees Of The University Of Pennsylvania | Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių |
| KR20240110996A (ko) * | 2015-02-12 | 2024-07-16 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 면역 관문 저해제와 조합한 플리나불린의 용도 |
| SG10202008673WA (en) * | 2015-03-06 | 2020-10-29 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| NZ778329A (en) * | 2017-03-13 | 2026-03-27 | Beyondspring Pharmaceuticals Inc | Compositions of plinabulin and use thereof |
-
2019
- 2019-05-30 JP JP2020567029A patent/JP7500438B2/ja active Active
- 2019-05-30 WO PCT/US2019/034726 patent/WO2019232257A1/en not_active Ceased
- 2019-05-30 EP EP19810149.5A patent/EP3801524B1/en active Active
- 2019-05-30 US US17/059,694 patent/US20210161888A1/en not_active Abandoned
- 2019-05-30 KR KR1020207036949A patent/KR102790127B1/ko active Active
- 2019-05-30 CA CA3101612A patent/CA3101612A1/en active Pending
- 2019-05-30 MX MX2020012799A patent/MX420412B/es unknown
- 2019-05-30 ES ES19810149T patent/ES3060133T3/es active Active
- 2019-05-30 AU AU2019278886A patent/AU2019278886B2/en active Active
- 2019-05-30 DK DK19810149.5T patent/DK3801524T3/da active
- 2019-05-30 CN CN201980050963.3A patent/CN112543636B/zh active Active
-
2025
- 2025-05-23 US US19/217,307 patent/US20250375440A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210015875A (ko) | 2021-02-10 |
| EP3801524A4 (en) | 2022-03-02 |
| CN112543636B (zh) | 2024-03-01 |
| AU2019278886B2 (en) | 2025-03-20 |
| AU2019278886A1 (en) | 2020-12-24 |
| JP7500438B2 (ja) | 2024-06-17 |
| DK3801524T3 (da) | 2026-02-02 |
| US20250375440A1 (en) | 2025-12-11 |
| US20210161888A1 (en) | 2021-06-03 |
| CA3101612A1 (en) | 2019-12-05 |
| CN112543636A (zh) | 2021-03-23 |
| JP2021525768A (ja) | 2021-09-27 |
| MX2020012799A (es) | 2021-03-25 |
| EP3801524A1 (en) | 2021-04-14 |
| ES3060133T3 (en) | 2026-03-25 |
| KR102790127B1 (ko) | 2025-04-03 |
| WO2019232257A1 (en) | 2019-12-05 |
| EP3801524B1 (en) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012799A (es) | Composicion y metodo para tratar el cancer asociado con mutacion del egfr. | |
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| CR20190376A (es) | Formulaciones de anticuerpos de her2 subcutáneas | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| CL2021000149A1 (es) | Composiciones anti-cd112r y métodos | |
| MX2021003765A (es) | Proteínas il-12 de fusión a fc heterodimérico. | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| GEAP202115055A (en) | Anti-cd27 antibodies | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| MX389560B (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| MX2024014237A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2020005344A (es) | Compuestos de pirazolopiridinona. |